ZYUS Life Sciences Corporation (TSXV:ZYUS)

Market Cap	58.86M
Revenue (ttm)	481.00K
Net Income (ttm)	-33.81M
Shares Out	76.44M
EPS (ttm)	-0.47
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,500
Average Volume	26,575
Open	0.7400
Previous Close	0.7400
Day's Range	0.7100 - 0.7400
52-Week Range	0.5500 - 1.1100
Beta	n/a
RSI	58.85
Earnings Date	May 8, 2025

About ZYUS Life Sciences

ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates in Canada, the United States, Australia, and the European Union. The company offers Trichomylin, a softgel capsules with fixed dose combination of cannabinoids formulated that is phase 2 clinical trial for the treatment of chronic pain in adults caused due to musculoskeletal injuries, arthritis, and cancer. ZYUS Life Sciences Corporation was founded in 2018 and is headquartered in Saskatoon, Canada.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2018
• Country: Canada
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: ZYUS

Financial Performance

In 2024, ZYUS Life Sciences's revenue was 481,000, an increase of 37.04% compared to the previous year's 351,000. Losses were -33.81 million, -20.63% less than in 2023.